Sulis Therapeutics - Taking the STING out of autoimmune diseases

First in class targeted STING INHIBITION

At Sulis Therapeutics, we're pioneering new treatments for systemic sclerosis and other diseases of inflammation and fibrosis. Inspired by Sulis, the Celtic goddess of healing and strength, and based on a deep understanding of the molecular pathways that drive these diseases, our lead program is based around potent and selective inhibitors of STING (STimulator of INterferon Genes).

Our mission is to bring transformative, life-enhancing therapies to patients worldwide, offering healing and hope through cutting-edge science and a focus on the needs of those living with inflammatory diseases.

SCIENCE

OUR SCIENCE

STING inhibitor program

Our lead project focuses on targeted degraders of STING (STimulator of INterferon Genes), a protein that plays a key role in triggering the immune response during viral infections and cancer, but which has been shown to also drive chronic inflammation in a number of autoimmune diseases. Our preclinical research on the targeted inhibition of STING received the award for best basic and translation research abstract at the 2024 EULAR annual congress.

OUR TEAM

Our founder team at Sulis Therapeutics brings together extensive experience and dedication to advancing treatments for systemic sclerosis and inflammatory diseases. Our diverse backgrounds and collaborative approach drive our mission to deliver transformative therapies to patients worldwide.
  • Claus E. Olesen, CEO
  • Richard Bethell, Head of R&D
  • Line Slemming, Head of Legal
  • Martin R. Jakobsen, Head of Biology
Photo:  Esben Zøllner Olesen for BioInnovation Institute. From left, Richard Bethell, Pernille Noer, Line Slemming, Martin Roelsgaard Jakobsen and Claus Elsborg Olesen.
About US

NEWS

August 2024:

We are thrilled to share that BioInnovation Institute has awarded Sulis Therapeutics funding to support our lead project – taking the STING out of autoimmune diseases. A huge thank you to BII for believing in our vision.

https://bii.dk/news/bii-welcomes-twelve-new-companies-to-its-venture-lab-program-2/https://bii.dk/news/bii-welcomes-twelve-new-companies-to-its-venture-lab-program-2/


June 2024: Sulis Therapeutics have received an EULAR Abstract Award 2024

https://congress.eular.org/abstract_awards.cfm



Danish START-UP

Sulis Therapeutics ApS
CVR No. 44445832
CAtCH UP
CONTACT
AdDress

Inge Lehmanns Gade 10

8000 Aarhus C

Danmark

 

Copyright 2024 ©